The Diagnostic Specialty Antibodies Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Diagnostic Specialty Antibodies Market:
https://www.thebusinessresearchcompany.com/report/diagnostic-specialty-antibodies-global-market-report
According to The Business Research Company’s Diagnostic Specialty Antibodies Global Market Report 2024, The diagnostic specialty antibodies market size has grown strongly in recent years. It will grow from $28.33 billion in 2023 to $29.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to advancements in biotechnology, emergence of personalized medicine, increased disease understanding, immunoassay and diagnostic techniques, rise of companion diagnostics.
The diagnostic specialty antibodies market size is expected to see strong growth in the next few years. It will grow to $37.75 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to expanding disease biomarkers, rapid point-of-care testing, emerging infectious diseases, biosimilar and generic development, ai and machine learning integration. Major trends in the forecast period include technological advancements in assay development, integration of nanotechnology, enhanced specificity and selectivity, integration with wearable devices, continuous assay miniaturization.
The growing patient pool for HIV diagnosis is expected to propel the growth of the diagnostic specialty antibodies market going forward. The growing patient pool of HIV diagnoses refers to an increasing number of individuals who are being diagnosed with HIV (Human Immunodeficiency Virus). As the number of individuals being diagnosed with HIV increases, the market for diagnostic specialty antibodies expands, creating opportunities for manufacturers to develop and supply specialized antibody-based diagnostic products for HIV testing, enabling the detection of specific biomarkers associated with the virus and aiding in the early detection and monitoring of HIV infection. For instance, in July 2022, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), the Switzerland-based UN program dedicated to addressing the global HIV or AIDS epidemic, the global population living with HIV increased by 1.6% from 37.8 million in 2020 to 38.4 million in 2021. Further, there were approximately 1.5 million new HIV infections reported in 2021. Therefore, the growing patient pool of HIV diagnoses is driving the growth of the diagnostic specialty antibodies market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12241&type=smp
The diagnostic specialty antibodies market covered in this report is segmented –
1) By Antibody Type: Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies
2) By Application: Hepatitis, Tuberculosis, Dengue, Oncology, Human Immunodeficiency Virus (HIV), Infectious Disease, Other Applications
3) By End User: Diagnostic Laboratories, Hospitals
Product innovation is a key trend gaining popularity in the diagnostic specialty antibodies market. Major companies operating in the diagnostic specialty antibodies market are focused on introducing novel products and solutions to strengthen their position in the market. For instance, in January 2023, Creative Diagnostics, a US-based company providing raw materials, antibodies, and reagents for the biotechnology industry, launched 1,000 new targets, including carrier-free formulations and conjugated antibodies, expanding its monoclonal antibody capabilities and product offerings to serve customers worldwide. The newly introduced monoclonal antibodies are designed to be versatile and high-performing tools for various applications. They can be utilized as ELISA (enzyme-linked immunoassay) detection tools in direct, indirect, and sandwich ELISA methods, offering improved specificity due to their single-epitope recognition. These antibodies have undergone rigorous validation and are suitable for a wide range of applications, including Western blotting (WB), flow cytometry (FC), immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), and immunoprecipitation (IP).
The diagnostic specialty antibodies market report table of contents includes:
1. Executive Summary
2.Diagnostic Specialty Antibodies Market Characteristics
3.Diagnostic Specialty Antibodies Market Trends And Strategies
4.Diagnostic Specialty Antibodies market analysis
5.Diagnostic Specialty Antibodies Market Size And Growth
6. Diagnostic Specialty Antibodies Segmentation
7.Diagnostic Specialty Antibodies Regional And Country Analysis
.
.
.
27. Diagnostic Specialty Antibodies Competitive Landscape And Company Profiles
28.Diagnostic Specialty Antibodies Key Mergers And Acquisitions
29.Diagnostic Specialty Antibodies Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- F. Hoffmann-La Roche AG
- Sanofi SA
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
